1. BUSINESS PRESENTATION
March 2015
ArkGen Pharma Private Limited

2. Promoters
Vision and Mission
Company Description
Product / Service
The market
Strategy and Implementation
Management Team
Disclaimer
BUSINESS PLAN
Content

3. BUSINESS PLAN
Promoters
Personal
information
•Dr P N Reddy, President
•C-32 , Hoskote Ind. Area,
Bangalore
•+91 9980542732
•Reddy.pn@arkgenpharma.com
• MTech, PhD, Post Doc Experience
•18 Years Experience
•Worked in GE India, Bangalore,
Apotex India, Bangalore
• Promoted a Start up Company
Creative Organics in 2008
Co-Promoted ArkGen in August
2014
Personal
information
•Dr P M Akbarali, Chairman and
Managing Director
• 201,PSP Square , 3rd Floor, Green
Glenn Layout, Bangalore 560103
• +91 9880700424
• akbar@arkgenpharma.com
• MSc, PhD in Chemistry, MBA
• 25 Years in the Pharma
companies in Cipla, Strides Arco
Lab and Apotex India
• Promoted Plama Labs Ltd in 1995
•MD Apotex Pharmachem India
Nov 2004- May2014
•Promoted ArkGen in August 2014

4. Values and Visions
•One of the renouned API RSM (Regulatory Starting
Materials) Manufacturers of the world
•Creating value through Research
•Strong Intellectual Property Management and
Regulatory back up.
•Expertise in the development of novel, non-infringing
and cost-effective Processes.
•Absolute assurance of best quality Regulatory
Starting Materials.
Missions and Goals
•To reach substantial value in 2 years
•Quality as per ICH Guidelines
•Quality Regulatory Starting Materials meeting the
stingent regulatory expectations
•Speed to market for customers and support their
Regulatory commitments.
•Timely delivery and prompt response to all queries of
the customers
BUSINESS PLAN
Vision and Mission

5. BUSINESS PLAN
Company Description
Company History
•Promoted by Technocrats having
business Experience
•Incorporated in August 2014 in
Bengaluru, India 560103
•Focus on Quality Products to the
Healthcare Industry.
•Regulatory Starting Materials for
the API Industry
Ownership
•It is a Private Limited Company held
by Shares
Facilities and Location(s):
• State of Art R&D Center in Bangalore
• Leased Manufacturing Facilities;
Facility 1 at Bidar, Karnataka and
Facility 2 at Bangalore

6. LOCATED AT PLOT NO 106&107, KIADB AREA BIDAR, KARNATAKA
INDIA
• Production block with 18 reactors totaling 50 m3
• Cryo facility from 630 lits to 4000 lits capacity – 4 nos
• Clean room with GL- 3KL and SS - 3KL reactors
• Distillation column
• Hydrogenator 1KL capacity upto 15 kg working pressure
• 8000 sft. Warehouse
• 1 lakh litres solvent storage capacity
• MEE with effluent treatment facility, 30 KL per day capacity
• RO Plant capcity 4000 lph.
• Hot oil 2 lakh kilo calories
• Fire hydrant System, etc.
6
FACILITY 1 KSHATRIYA LABORATORIES PVT LTD

7. LOCATED AT Plot.No:11/2, KIADB Industrial Area Attibele Hobli
Anekal Taluk, Bangalore, KARNATAKA INDIA
• Production block with 12 reactors totaling 32 m3
• facility from 900 lits to 4000 lits capacity
• Kilo Lab Facility
• Well Equipped QC Lab
• 5000 sft. Warehouse
• ISO 9001:2008 Certified Company (NQA)
7
FACILITY 2 SONIA ORGANICS

8. • All Types of Alkali Metal Reactions
• Cryogenic Reactions
• Hydrogenation
• Grignard Reaction
• Ammonalysis
• Oxidation
• Acetylation
• Friedel Crafts Reactions
• Halogenations
• Condensation
• Nitration
• High Vacuum Distillations etc.
REACTION CAPABILITIES
8

9. BUSINESS PLAN
API Regulatory Starting
Materials Fingolimod Palpiradone
Letrazole Fesoteride
Prsugrel Ranolazine
Dasatinib Erlotinib
Pregabalin Nilotinib
Levothyroxine Olmesatran
Febuxostat Rosuvastatin
Etravirine
Sartraline
Timolol
Canagliflozen
Dolutegravir
Dabigatran
PRODUCT UNDER DEVELOPMENT:
1. Efinaconazole
2. Droxidopa
3. Idelalisib
4. Dapgliflozin
5. Empagliflozin
6. Afatinib
7. Ibrutinib
8. Pazopanib
Note:- Products Protected by Patent in the Country are not offered for sale to that
Country.

10. BUSINESS PLAN
Management Team
Professional with a proven record from
reputed pharma companies are part of the
Management Team comprising of R&D,
Regulatory, Quality Assurance, IP, EHS ,
Operations , Project and Engineering

11. Disclaimer
Forward-looking statements that can be identified in the slides given above,
or from by express or implied discussions regarding potential future business
from ArkGen. Undue reliance should not be put on these statements as
these are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown
risks and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
Many factors influence the event not limited to the company's ability to
obtain or maintain proprietary intellectual property protection; general
economic and industry conditions; global trends toward health care cost
containment, including ongoing pricing pressures; unexpected regulatory
actions or delays or government regulation generally; unexpected
manufacturing issues; the uncertainties inherent in research and
development etc